Biogen teams up with gene-editing startup Scribe on ALS program

Biogen teams up with gene-editing startup Scribe on ALS program

Source: 
Pharmaforum
snippet: 

Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen.